DIA Biosimilars 2013

RPS

PRA, RPS merger completed

Wednesday, September 25, 2013 12:23 PM

CRO PRA International has completed its merger with ReSearch Pharmaceutical Services (RPS) and the closing of the acquisition by Kohlberg Kravis Roberts.  

More... »

Cenduit: Now with Patient Reminders

RPS, PRA to merge under KKR ownership

Wednesday, July 31, 2013 01:51 PM

Global investment firm KKR has signed a definitive agreement to acquire ReSearch Pharmaceutical Services (RPS), a global CRO, from Warburg Pincus.

More... »

CRF Health – eCOA Forum

ReSearch Pharmaceutical, Asklep create joint venture in Japan

Friday, March 29, 2013 03:03 PM

ReSearch Pharmaceutical Services (RPS), a global CRO, and Asklep, a Japanese CRO, have created a joint venture company (JVC) to deliver leading-edge R&D outsourcing solutions in Japan to the biopharmaceutical and medical device industries. 

More... »

RPS appoints Stephen Kasay as CIO

Thursday, August 30, 2012 03:02 PM

ReSearch Pharmaceutical Services (RPS), a Fort Washington, Penn.-based next generation global CRO that provides comprehensive phase I-IV clinical development solutions, has appointed Stephen Kasay as chief information officer.

More... »

Survey: Top CROs doubled workforce over past decade

Monday, October 24, 2011 08:02 AM

Over the last 10 years, the top nine global CROs have more than doubled their workforce, which now exceeds 72,000 employees, and their revenues have increased at a compound annualized rate of 11% as they increasingly play a larger and more integral role in the drug development infrastructure, according to a new Association of Clinical Research Organizations (ACRO) member survey.

More... »

Carlyle Partners, Hellman & Friedman to acquire PPD for $3.9 billion, take the CRO private

Monday, October 10, 2011 08:02 AM

It’s official: Large equity investors Carlyle Partners and Hellman & Friedman Capital Partners are buying publicly traded PPD, taking the CRO private.

More... »

PRA on the block, too?

Monday, August 8, 2011 08:02 AM

There was much hoopla made about PPD possibly being for sale after the Wall Street Journal published a story saying as much in mid-July. But what about its smaller competitor, PRA International?

More... »

RPS to Raise $100 Million in IPO

Wednesday, June 23, 2010 08:15 AM

ReSearch Pharmaceutical Services (RPS) plans an initial public offering in the U.S. on the Nasdaq exchange. The Fort Washington, Pa.-based contract research organization (CRO ) seeks to raise $100 million from the IPO.

More... »

RPS on Global Acquisition Spree

Monday, April 13, 2009 08:00 AM

ReSearch Pharmaceutical Services’ (RPS) plan to acquire a small contract research organization (CRO) in China will expand the company’s capabilities in Asia, but the deal is also part of a larger plan to expand RPS throughout the world by multiple acquisitions.

More... »

RPS to Acquire Paramax for $1M

Thursday, April 2, 2009 04:00 PM

ReSearch Pharmaceutical Services (RPS) has entered into an agreement to acquire Chinese contract research organization (CRO) Paramax International for $1 million in cash and 530,973 shares of RPS common stock.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs